Pro-dex Stock News

IRVINE, CA / ACCESSWIRE / May 2, 2024 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2024 third quarter ended March 31, 2024.

IRVINE, CA / ACCESSWIRE / February 8, 2024 / PRO-DEX, INC. (NasdaqCM:PDEX) today announced financial results for its fiscal 2024 second quarter ended December 31, 2023.

While the forward-looking mood for the equities sector may be pivoting in a positive direction, there are still opportunities among undervalued stocks with strong growth potential. Sure, the sector ha

IRVINE, CA / ACCESSWIRE / November 2, 2023 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2024 first quarter ended September 30, 2023.

PHOENIX, AZ / ACCESSWIRE / October 26, 2023 / The Stock Day Podcast welcomed Pro-Dex, Inc. (NASDAQ:PDEX)("the Company"), a company that specializes in the design, development, and manufacture of autoc

PITTSBURGH, July 13, 2023 (GLOBE NEWSWIRE) -- Sopheon, the InnovationOps software company, today announced the acquisition of the business and assets of Prodex Systems Australasia (“Prodex”), a sp

Pro-Dex (NASDAQ: PDEX) is one of 196 public companies in the Surgical & medical instruments industry, but how does it contrast to its peers? We will compare Pro-Dex to related businesses based on the strength of its earnings, dividends, institutional ownership, valuation, risk, profitability and analyst recommendations. Analyst Ratings This is a summary of current []

Pro-Dex (NASDAQ: PDEX) is one of 195 public companies in the Surgical & medical instruments industry, but how does it compare to its competitors? We will compare Pro-Dex to related businesses based on the strength of its analyst recommendations, dividends, profitability, valuation, earnings, institutional ownership and risk. Profitability This table compares Pro-Dex and its competitors []

Pro-Dex (NASDAQ: PDEX) is one of 195 publicly-traded companies in the Surgical & medical instruments industry, but how does it compare to its rivals? We will compare Pro-Dex to similar companies based on the strength of its profitability, analyst recommendations, earnings, valuation, institutional ownership, dividends and risk. Volatility & Risk Pro-Dex has a beta of []

Avoiding – not evading – the IRS. Income tax minimization and estate tax avoidance.

Pro-Dex (NASDAQ: PDEX) is one of 192 publicly-traded companies in the Surgical & medical instruments industry, but how does it contrast to its rivals? We will compare Pro-Dex to related businesses based on the strength of its analyst recommendations, dividends, institutional ownership, earnings, profitability, valuation and risk. Earnings & Valuation This table compares Pro-Dex and []

IRVINE, CA / ACCESSWIRE / November 15, 2021 / PRO-DEX, INC. (NasdaqCM:PDEX) today announced financial results for its fiscal 2022 first quarter ended September 30, 2021. The Company also filed its

A History Of Strong Growth Rates: Pro-Dex On Sale